

# See a Social Security Number? Say Something! Report Privacy Problems to https://public.resource.org/privacy Or call the IRS Identity Theft Hotline at 1-800-908-4490



# Form 990-PF

Department of the Treasury

Internal Revenue Service

## **Return of Private Foundation**

### or Section 4947(a)(1) Nonexempt Charitable Trust Treated as a Private Foundation

Note. The foundation may be able to use a copy of this return to satisfy state reporting requirements

OMB No 1545-0052

2009

Foi	calen	dar year 2009, or tax year be	ginning	, 200	9, and	ending		, 20
G	Check	all that apply:	turn 🔲 Initial re	eturn of a former p	ublic cl	harity	☐ Final return	
						ne change		
Us	se the	RS Name of foundation				A Employer	identification number	
	label.	Sanofi-Aventis Patient Ass					43-1614543	
0	therwi print	, , , , , , , , , , , , , , , , , , , ,		o street address) Ro	om/suite	B Telephone	number (see page 10 o	f the instructions)
	or type	55 Corporate Drive A AX	DEPARTMENT				908-981-5000	
Se	e Spec	ific City or town, state, and ZIP code	e			C If exempt	ion application is pendin	g, check here 🕨 🗌
		ons. Bridgewater, NJ 08807				, ~	n organizations, check	_
H		type of organization:					n organizations meeting here and attach compu	
Ц		n 4947(a)(1) nonexempt charita					foundation status was	_
1		arket value of all assets at	J Accounting method:	: ☑ Cash ☐ A	ccrual		07(b)(1)(A), check here	▶□
		year (from Part II, col. (c),					ndation is in a 60-mont	
Б	line 16		(Part I, column (d) must be	on cash basis )	r -	under se	ction 507(b)(1)(B), checl	
	art I	Analysis of Revenue and E amounts in columns (b), (c), and (d	Expenses (The total of f) may not necessarily equal	(a) Revenue and	(b) Net	investment	(c) Adjusted net	(d) Disbursements for charitable
		the amounts in column (a) (see page	ge 11 of the instructions))	expenses per books	l ir	come	income	purposes (cash basis only)
	4			321,376,881	<del> </del>	<del></del>		
	1 2	Contributions, gifts, grants, etc., re Check ► ☐ if the foundation is no	·	021,070,001	-			
	3	Interest on savings and tempor	· ·		ļ			
	4	Dividends and interest from se	- r		·			
	5a	Gross rents						
	b	Net rental income or (loss)						
<u>o</u>	6a	Net gain or (loss) from sale of	assets not on line 10					
Revenue	ь	Gross sales price for all assets on I	r					
Š	7	Capital gain net income (from	Part IV, line 2)			0		
_	8	Net short-term-capital gain .	[		<u> </u>			
8	R理C							
·	_10a_	-Gross-sates tessue urns and allow	vances		ļ			
1	b	ALPE GLAGA T						
1	MAX	Gross profit or Joss) (attach s		0				
L_	11	Other income (attach schedul		224 276 004				
-		Total. Add lines 1 through 11		321,376,881		0	0_	· · · · · · · · · · · · · · · · · · ·
— <b>⊘</b>	14	Compensation of officers, directly of the compensation of officers and officers and officers and officers and officers are considered.					-	
'n	15	Pension plans, employee ben	- I					
ğ	16a	Legal fees (attach schedule)						
ω	1	Accounting fees (attach sched	· · · · · · · · · · · · · · · · · · ·					
tive Expenses	C	Other professional fees (attac	·					
	17	Interest						
ist	18	Taxes (attach schedule) (see pag	P P					
Ë	19	Depreciation (attach schedule	e) and depletion					
듈	20	Occupancy						
P	21	Travel, conferences, and mee						<u> </u>
ā	22							
ğ	23	Other expenses (attach sched						
atii	24	Total operating and admi		_		_		_
Operating and Administra		Add lines 13 through 23	, , , , , , , , , , , , , , , , , , ,	0	ļ	0	0	224 276 994
Ö	25	Contributions, gifts, grants partotal expenses and disbursements		321,376,881 321,376,881		0	0	321,376,881 321,376,881
_	26		aria. Aud intes 24 and 25	321,370,081		<u> </u>	<u> </u>	321,370,001
	27	Subtract line 26 from line 12: Excess of revenue over expens	see and dishumannants	0	1			
	a	Net investment income (if no			<b>-</b>	0		
	b	Adjusted net income (if nega					0	<del></del>
		najustou net moome (ii nego	<u> </u>		<u> </u>			000 DE

10

-		Attached schedules and amounts in the description column	Beginning of year		End of	f year
ra	rt II	Balance Sheets Attached schedules and amounts in the description column should be for end-of-year amounts only. (See instructions)	(a) Book Value	(b) Book Valu	ie	(c) Fair Market Value
	1	Cash-non-interest-bearing				
	2	Savings and temporary cash investments				
	3	Accounts receivable ►	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
		Less: allowance for doubtful accounts ▶				
	4	Pledges receivable ▶				
	7	Less: allowance for doubtful accounts ▶				<del></del>
	5	Grants receivable				
	6	Receivables due from officers, directors, trustees, and other			$\neg$	·
	U	disqualified persons (attach schedule) (see page 16 of the			ļ	
		instructions)				· · · · · · · · · · · · · · · · · · ·
	7	Other notes and loans receivable (attach schedule) ▶				
Ś		Less: allowance for doubtful accounts ▶				
Assets	8	Inventories for sale or use				
1St	9	Prepaid expenses and deferred charges				
1	10a	Investments – U.S. and state government obligations (attach schedule)				
	b	Investments - corporate stock (attach schedule)				
	С	Investments—corporate bonds (attach schedule)				
	11	Investments—land, buildings, and equipment: basis ▶				
		Less. accumulated depreciation (attach schedule) ▶				
	12	Investments-mortgage loans		-		
	13	Investments—other (attach schedule)				
	14	Land, buildings, and equipment: basis ▶				
		Less: accumulated depreciation (attach schedule) ▶				
	15	Other assets (describe ▶)				
	16	Total assets (to be completed by all filers—see the				
		instructions. Also, see page 1, item l)	0		0	0
_	17	Accounts payable and accrued expenses				
	18	Grants payable				
ies	19	Deferred revenue				
Liabilities	20	Loans from officers, directors, trustees, and other disqualified persons				
ap	21	Mortgages and other notes payable (attach schedule)		-	-	
Ξ	22	Other liabilities (describe ►)			-	
	23	Total liabilities (add lines 17 through 22)	0		0	
		Foundations that follow SFAS 117, check here				
S		and complete lines 24 through 26 and lines 30 and 31.				
Balances	24	Unrestricted				
ā	25	Temporarily restricted				
Ba	26	Permanently restricted				
Net Assets or Fund		Foundations that do not follow SFAS 117, check here ▶ ☐ and complete lines 27 through 31.				
Ť	27	Capital stock, trust principal, or current funds		1		
0	28	Paid-in or capital surplus, or land, bldg., and equipment fund				
ė	29	Retained earnings, accumulated income, endowment, or other funds				
SS	30	Total net assets or fund balances (see page 17 of the				
t A	-	instructions)	۰ ا		0	
Se	31	Total liabilities and net assets/fund balances (see page 17				
_	"	of the instructions)	٥		0	
P۵	rt III	Analysis of Changes in Net Assets or Fund Balances	<u> </u>	L		
4	Tota	al net assets or fund balances at beginning of year—Part II, colu	mn (a), line 30 (mus	st agree with	· · · · · · · · · · · · · · · · · · ·	
•		of-year figure reported on prior year's return)			1	0
_		er amount from Part I, line 27a			2	0
2	- CAL	er increases not included in line 2 (tamins)			3	
		er increases not included in line 2 (itemize)			4	0
		Innes 1, 2, and 3			5	<u> </u>
5	Deci	reases not included in line 2 (itemize) ► al net assets or fund balances at end of year (line 4 minus line 5)—	Part II column (b) li	ne 30	6	0
0	, iota	arrier assers or futio balances at end or year filling 4 fillings line 3)—	. a. t 11, 00 tal (111 (D), 11	<del></del>		

Part	(a) List and describe the	Losses for Tax on Investme kind(s) of property sold (e.g., real estate se, or common stock, 200 shs MLC Co.	9,	(b) How acquired P-Purchase D-Donation		acquired day, yr)	(d) Date sold (mo , day, yr )
<b>.</b>	2 2327 2330			U-Donation	<del>                                     </del>		
<u>1a</u> b			<del></del>	<del> </del>	<del>                                     </del>		
c			<del></del>				
					<del> </del>		
<u>e</u>		(D Depresented allowed	(=) Cost or	other basis		(h) Ga	n or (loss)
	(e) Gross sales price	(f) Depreciation allowed (or allowable)		nse of sale			f) minus (g)
		<del></del>			<del>                                     </del>		
<u>a</u>							
<u>b</u> _			<del></del>				
					ļ		
<u>d</u>			_		<del> </del>		
е	Complete ask for contacts	was some a solume (b) and sweed	by the foundation	on 12/21/60			
	Complete only for assets sho	wing gain in column (h) and owned					l (h) gain minus t less than -0-) <b>or</b>
	(i) F M.V as of 12/31/69	(j) Adjusted basis as of 12/31/69		s of col (ı) (ı), ıf any			rom col (h))
		23 01 12/01/03	070,00				
a							<del> </del>
<u> </u>					ļ		
<u> </u>							
d					ļ		
е_				<del></del>	<del>                                     </del>		
2	Capital gain net income or		also enter in Pa				
_	. •	( 11 (1055)	, enter -0- in Pa		2		
3		n or (loss) as defined in sections					
		, line 8, column (c) (see pages 1	3 and 17 of the	instructions).			
	If (loss), enter -0- in Part I,			J	3		<del></del>
Part	V Qualification Und	er Section 4940(e) for Redu	iced Tax on N	let Investmen	t Incom	e	
Was t	tion 4940(d)(2) applies, leaven the foundation liable for the s." the foundation does not	section 4942 tax on the distribution qualify under section 4940(e).	itable amount of o not complete	any year in the this part.	base per	iod?	☐ Yes ☐ No
1		ount in each column for each ye			ns before	making a	any entries.
	(a)	(b)		(c)			(d)
Cal	Base period years endar year (or tax year beginning in)	Adjusted qualifying distribution	s Net value o	f noncharitable-use a	assets		tribution ratio divided by col. (c))
	2008	260,74	0,827				0
	2007	177,41					0
	2006	221,67	6,217				0
	2005	217,84					0
	2004	114,66					0
	2001		<u>· · · · · · · · · · · · · · · · · · · </u>				
2	Total of line 1, column (d)				.   2	<u>,</u>	(
3	Average distribution ratio	for the 5-year base period—div					
•		dation has been in existence if le					
	number of yours are round			• • • • •	·	<del>*                                       </del>	
4	Enter the net value of non	charitable-use assets for 2009 f	rom Part X, line	5	. 4		
5	Multiply line 4 by line 3					5	
6	Enter 1% of net investmen	nt income (1% of Part I, line 27b	)		. 6	<u> </u>	
7	Add lines 5 and 6				. 7	,	
8	Enter qualifying distribution	ons from Part XII, line 4			. [		321,376,88
	If line 8 is equal to or great Part VI instructions on page	ater than line 7, check the box inge 18.	n Part VI, line 1t	o, and complete	that part	using a 1	1% tax rate. See th

Part '	Excise Tax Based on Investment Income (Section 4940(a), 4940(b), 4940(e), or 4948—see page 18	of the	inst	truction	ons)
1a	Exempt operating foundations described in section 4940(d)(2), check here ▶ ☐ and enter "N/A" on line 1.  Date of ruling or determination letter: (attach copy of letter if necessary—see instructions)				
b	Domestic foundations that meet the section 4940(e) requirements in Part V, check				
	here ▶ ☐ and enter 1% of Part I, line 27b				
С	All other domestic foundations enter 2% of line 27b. Exempt foreign organizations enter 4% of Part I, line 12, col. (b)	<del></del>			
2	Tax under section 511 (domestic section 4947(a)(1) trusts and taxable foundations only. Others enter -0-)				
3	Add lines 1 and 2			0	
4	Subtitle A (income) tax (domestic section 4947(a)(1) trusts and taxable foundations only. Others enter -0-)				
5	Tax based on investment income. Subtract line 4 from line 3. If zero or less, enter -0			0	
6	Credits/Payments:				
а	2009 estimated tax payments and 2008 overpayment credited to 2009   6a				1
b	Exempt foreign organizations—tax withheld at source 6b			-	
Ç	Tax paid with application for extension of time to file (Form 8868) . 6c 6c				
d	Backup withholding erroneously withheld 6d				
7	Total credits and payments. Add lines 6a through 6d			0	
8	Enter any <b>penalty</b> for underpayment of estimated tax. Check here  if Form 2220 is attached  8				
9	Tax due. If the total of lines 5 and 8 is more than line 7, enter amount owed ▶ 9			0	
10	Overpayment. If line 7 is more than the total of lines 5 and 8, enter the amount overpaid ▶ 10			0	
11	Enter the amount of line 10 to be: Credited to 2010 estimated tax ▶ Refunded ▶ 11			0	L
Part					г <del></del>
1a	During the tax year, did the foundation attempt to influence any national, state, or local legislation or did			Yes	No
_	participate or intervene in any political campaign?		1a		<b>✓</b>
b	Did it spend more than \$100 during the year (either directly or indirectly) for political purposes (see page of the instructions for definition)?	. [	1b		1
	If the answer is "Yes" to 1a or 1b, attach a detailed description of the activities and copies of any material published or distributed by the foundation in connection with the activities.	als			
С	Did the foundation file Form 1120-POL for this year?	. [	1c		<b>\</b>
d	Enter the amount (if any) of tax on political expenditures (section 4955) imposed during the year:  (1) On the foundation. ▶ \$  (2) On foundation managers. ▶ \$				
е	Enter the reimbursement (if any) paid by the foundation during the year for political expenditure tax impose on foundation managers. ▶ \$	d			
2	Has the foundation engaged in any activities that have not previously been reported to the IRS? If "Yes," attach a detailed description of the activities.	.  -	2		<b>✓</b>
3	Has the foundation made any changes, not previously reported to the IRS, in its governing instrument, articles incorporation, or bylaws, or other similar instruments? If "Yes," attach a conformed copy of the changes.	s of _	3		1
4a	Did the foundation have unrelated business gross income of \$1,000 or more during the year?	<b>⊢</b>	4a		7
b	If "Yes," has it filed a tax return on <b>Form 990-T</b> for this year?		4b	N	A
5	Was there a liquidation, termination, dissolution, or substantial contraction during the year?	. [	5		1
	If "Yes," attach the statement required by General Instruction T.	Γ			
6	Are the requirements of section 508(e) (relating to sections 4941 through 4945) satisfied either:				
	By language in the governing instrument, or	1			}
	• By state legislation that effectively amends the governing instrument so that no mandatory directions the	hat			}
	conflict with the state law remain in the governing instrument?	· ļ	6_	<b>/</b>	
7	Did the foundation have at least \$5,000 in assets at any time during the year? If "Yes," complete Part II, col. (c), and Part X		7	<b>/</b>	
8a	Enter the states to which the foundation reports or with which it is registered (see page 19 of instructions) ▶				
b	If the answer is "Yes" to line 7, has the foundation furnished a copy of Form 990-PF to the Attorney Gene (or designate) of each state as required by General Instruction G? If "No," attach explanation	1-	8b	1	
9	Is the foundation claiming status as a private operating foundation within the meaning of section 4942(j)(3)				
	4942(j)(5) for calendar year 2009 or the taxable year beginning in 2009 (see instructions for Part XIV on pa 27)? If "Yes," complete Part XIV	ige	9	j I	1
10	Did any persons become substantial contributors during the tax year? If "Yes," attach a schedule listing the names and addresses		10		1

		-	
Form	gan.	ヴェ	(2009)

P	ac	ıe	

Part	VII-A Statements Regarding Activities (continued)	-		_ <u>-</u> _
11	At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the	[	Г	
	meaning of section 512(b)(13)? If "Yes," attach schedule (see page 20 of the instructions)	11		✓
12	Did the foundation acquire a direct or indirect interest in any applicable insurance contract before			
	August 17, 2008?	12		✓
13	Did the foundation comply with the public inspection requirements for its annual returns and exemption application?	13	1	
	Website address ▶			
14		8-981-	5000	
	Located at ▶ 55 Corporate Drive, Bridgewater, NJ ZIP+4 ▶	0880	7	
15	Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of Form 1041—Check here	·····		▶ □
	and enter the amount of tax-exempt interest received or accrued during the year			_
Part	VII-B Statements Regarding Activities for Which Form 4720 May Be Required			
	File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.		Yes	No
1a	During the year did the foundation (either directly or indirectly):			
	(1) Engage in the sale or exchange, or leasing of property with a disqualified person?   Yes  No			}
	(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a			
	disqualified person?			
	(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person?   Yes			
	(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person?		1	
	(5) Transfer any income or assets to a disqualified person (or make any of either available for			
	the benefit or use of a disqualified person)?			
	(6) Agree to pay money or property to a government official? (Exception. Check "No" if the			
	foundation agreed to make a grant to or to employ the official for a period after			
	termination of government service, if terminating within 90 days.)			{
b	If any answer is "Yes" to 1a(1)–(6), did <b>any</b> of the acts fail to qualify under the exceptions described in Regulations			
	section 53.4941(d)-3 or in a current notice regarding disaster assistance (see page 20 of the instructions)?	1b	N	A
	Organizations relying on a current notice regarding disaster assistance check here		.,,	1
С	Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that			
	were not corrected before the first day of the tax year beginning in 2009?	1c		1
2	Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private	··-		<u> </u>
_	operating foundation defined in section 4942(j)(3) or 4942(j)(5)):	ļ.,	ļ	] ]
а	At the end of tax year 2009, did the foundation have any undistributed income (lines 6d and			
_	6e, Part XIII) for tax year(s) beginning before 2009?			i
	If "Yes," list the years ▶ 20 , 20 , 20 , 20			
b	Are there any years listed in 2a for which the foundation is <b>not</b> applying the provisions of section 4942(a)(2)			
	(relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to			
	all years listed, answer "No" and attach statement—see page 20 of the instructions.)	2b	N	A
c	If the provisions of section 4942(a)(2) are being applied to any of the years listed in 2a, list the years here.			
•				
За	▶ 20 , 20 , 20 , 20 Did the foundation hold more than a 2% direct or indirect interest in any business enterprise			
	at any time during the year?			
_	If "Yes," did it have excess business holdings in 2009 as a result of (1) any purchase by the foundation or			i
D	disqualified persons after May 26, 1969; (2) the lapse of the 5-year period (or longer period approved by the			
	Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or (3) the lapse of			
	the 10-, 15-, or 20-year first phase holding period? (Use Schedule C, Form 4720, to determine if the			
	foundation had excess business holdings in 2009.)	3b	N	Α
4a	Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes?	4a	<b>–</b>	<del>/</del>
b	Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its	70		
~	charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2009?	4b		1
	, , <u> </u>	<u> </u>		

orm	agn.	PF	120091

_	•
Pana	-

\_\_\_\_\_\_

Part	VII-B Statements Regarding Activities	TOF V	vnich Form	4/20	мау ве н	equire	<b>a</b> (contir	nue <u>d)</u>			
5a	During the year did the foundation pay or incur a	ny amo	ount to:								
	(1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))? .   Yes  No									1	
	(2) Influence the outcome of any specific public election (see section 4955); or to carry on,								1 .		
	directly or indirectly, any voter registration drive?										i
	(3) Provide a grant to an individual for travel, stu						Yes 🗌	✓ No			
	(4) Provide a grant to an organization other than										
	section 509(a)(1), (2), or (3), or section 4940(c	l)(2)? (s	ee page 22 c	of the in	structions)		TYes	✓ No			1
	(5) Provide for any purpose other than religious										
	purposes, or for the prevention of cruelty to	childrer	n or animals?				Yes	✓ No			i
b	If any answer is "Yes" to 5a(1)-(5), did any of the										
	Regulations section 53.4945 or in a current notice	regardi	ng disaster as	ssistanc	e (see page	22 of t	he instruc	tions)?	5b_	N	<u>A</u>
	Organizations relying on a current notice regards										
С	If the answer is "Yes" to question 5a(4), does t								1 .		1
	because it maintained expenditure responsibility	for the	grant?				Yes 🗌	☐ No	1		}
	If "Yes," attach the statement required by Regula										}
6a	Did the foundation, during the year, receive any	funds,	directly or in	directly	, to pay pre	emiums	_			J	]
	on a personal benefit contract?						☐ Yes	✓ No			
b	Did the foundation, during the year, pay premiun	ns, dire	ctly or indire	ctly, on	a personal	benefit	contract	?.	6b		<u> </u>
	If "Yes" to 6b, file Form 8870.						_				
	At any time during the tax year, was the foundation						Yes				
	If yes, did the foundation receive any proceeds of								7b		
Part	VIII Information About Officers, Direc	tors,	rustees, F	ounda	tion mana	agers,	Highly P	ald E	mploy	ees,	
	and Contractors		and th		nonostion	1000 0	000 00 00	f the in			
1	List all officers, directors, trustees, foundation		e, and average		mpensation		Contributions				
	(a) Name and address	hou	rs per week ed to position	(If not	paid, enter -0-)	emplo	yee benefit erred compe	plans	(e) Expe other	nse acc allowan	
	ry Irace	Presid	ent		0			0			0
	p Dr. Bridgewater NJ 08807		·								
	nt Gilhodes	V. Pres	sident		0			o			0
	p Dr. Bridgewater NJ 08807					<u> </u>					
	d Thomson	Teasu	er		0			0			0
	p Dr. Bridgewater NJ 08807										
	Silkworth	Secret	ary		0			0			0
	p Dr. Bridgewater NJ 08807	(.41-	Ab Ab								
2	Compensation of five highest-paid employee If none, enter "NONE."	s (oth	er than thos	e inclu	idea on iin	e 1—s	ee page	23 of 1	the ins	tructi	ons).
			T :		<u> </u>		(d) Contribu	tions to			
(	a) Name and address of each employee paid more than \$50,00	0	(b) Title, and a		(c) Comper	sation	employee	benefit	(e) Expe		
			devoted to p		'		plans and compens		otner a	ailowan	ces
	1/A								_		
	/-/-1			'		- 1					
			ł			1					
-											
								]			
Total r	number of other employees paid over \$50,000 .							. ▶			
-									orm <b>99</b>	0-PF	(2009)
		•									

Part VIII Information About Officer and Contractors (continue	s, Directors, Trustees, Foundation Manag	ers, Highly Paid Employees,
	ctors for professional services (see page 23 of t	he instructions). If none, enter "NONE."
(a) Name and address of each person		Type of service (c) Compensation
N/A		
Total number of others receiving over \$50,00	0 for professional services	▶ 0
Part IX-A Summary of Direct Char	table Activities	
List the foundation's four largest direct charitable act organizations and other beneficiaries served, conferen	vities during the tax year include relevant statistical informatices convened, research papers produced, etc	on such as the number of Expenses
1 N/A		
2		
3		
4		
Part IX-B Summary of Program-Re	elated Investments (see page 24 of the instr	ructions)
	made by the foundation during the tax year on lines 1 and 2	Amount
1 N/A		
2 N/A		
All other program-related investments. See page 24 of	the instructions	
3 N/A		
Total. Add lines 1 through 3	<u> </u>	▶   0 Form <b>990-PF</b> (2009

Part	Minimum Investment Return (All domestic foundations must complete this part. Foreit see page 24 of the instructions.)	ign fou	ındations,
1	Fair market value of assets not used (or held for use) directly in carrying out charitable, etc.,		
	purposes:	]	
_	Average monthly fair market value of securities	1a	
b	Average of monthly cash balances	1b	<del> </del>
С	Fair market value of all other assets (see page 24 of the instructions)	1c	
d	Total (add lines 1a, b, and c)	1d	
е	Reduction claimed for blockage or other factors reported on lines 1a and	] ]	
_	1c (attach detailed explanation)	<del> -</del>	
2	Acquisition indebtedness applicable to line 1 assets	2	<del></del>
3	Subtract line 2 from line 1d	3	<del></del>
4	Cash deemed held for charitable activities. Enter 1 1/2 % of line 3 (for greater amount, see page 25 of	,	
~	the instructions)	4	<del></del>
5 6	Net value of noncharitable-use assets. Subtract line 4 from line 3. Enter here and on Part V, line 4 Minimum investment return. Enter 5% of line 5	5	<del></del>
Part		6	
rait	foundations and certain foreign organizations check here ▶ ☐ and do not complete this part.)	opera	urig
1	Minimum investment return from Part X, line 6	1	<u> </u>
2a	Tax on investment income for 2009 from Part VI, line 5		<del></del>
b	Income tax for 2009. (This does not include the tax from Part VI.)	1	
С	Add lines 2a and 2b	2c	
3	Distributable amount before adjustments. Subtract line 2c from line 1	3	
4	Recoveries of amounts treated as qualifying distributions	4	
5	Add lines 3 and 4	5	
6	Deduction from distributable amount (see page 25 of the instructions)	6	
7	Distributable amount as adjusted. Subtract line 6 from line 5. Enter here and on Part XIII,		
	line 1	7	
Part	XII Qualifying Distributions (see page 25 of the instructions)		
<del></del>		г" г	
1	Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:		224 276 004
а	Expenses, contributions, gifts, etc.—total from Part I, column (d), line 26	1a	321,376,,881
b	Program-related investments—total from Part IX-B	1b	
2	purposes	2	
-	Amounts set aside for specific charitable projects that satisfy the:	-	
3	Suitability test (prior IRS approval required)	3a	
a	Cash distribution test (attach the required schedule)	3b	
ь 4	Qualifying distributions. Add lines 1a through 3b. Enter here and on Part V, line 8, and Part XIII, line 4	4	321,376,,881
5	Foundations that qualify under section 4940(e) for the reduced rate of tax on net investment income.	-	JE 1,010,,001
•	Enter 1% of Part I, line 27b (see page 26 of the instructions)	5	
6	Adjusted qualifying distributions. Subtract line 5 from line 4	6	321,376,,881
•	Note. The amount on line 6 will be used in Part V, column (b), in subsequent years when calculating qualifies for the section 4940(e) reduction of tax in those years.		
	quantities is: and descript to recognification or take in another years.		- 000 DE

art	XIII Undistributed Income (see page 26	of the instructions	)		
		(a)	(b)	(c)	(d)
1	Distributable amount for 2009 from Part XI,	Corpus	Years prior to 2008	2008	2009
	line 7				0
2	Undistributed income, if any, as of the end of 2009:				
a	Enter amount for 2008 only		0	0	
Ъ	Total for prior years: 20,20,20				
3 a	Excess distributions carryover, if any, to 2009: From 2004				
b	From 2004				
c	From 2006				
d	From 2007				
e	From 2008		i		
f	Total of lines 3a through e	992,346,245			
4	Qualifying distributions for 2009 from Part XII,				
	line 4: ▶ \$321,376,,881				
а	Applied to 2008, but not more than line 2a .			0	
b	Applied to undistributed income of prior years				
	(Election required—see page 26 of the instructions)		0		
С	Treated as distributions out of corpus (Election				
	required—see page 26 of the instructions) .			<del></del>	0
	Applied to 2009 distributable amount	321,376,,881			
е 5	Remaining amount distributed out of corpus Excess distributions carryover applied to 2009	321,370,,001			
3	(If an amount appears in column (d), the same				
	amount must be shown in column (a).)				
6	Enter the net total of each column as				
	indicated below:		ŀ		
а	Corpus. Add lines 3f, 4c, and 4e. Subtract line 5	1,313,723,126			
b	Prior years' undistributed income. Subtract				
	line 4b from line 2b		0		
С	Enter the amount of prior years' undistributed				
	income for which a notice of deficiency has				i
	been issued, or on which the section 4942(a) tax has been previously assessed		o		
d			U		
•	amount—see page 27 of the instructions .		o		1
е	Undistributed income for 2008. Subtract line				
_	4a from line 2a. Taxable amount—see page				
	27 of the instructions			0	
f	Undistributed income for 2009 Subtract lines				
	4d and 5 from line 1. This amount must be				
	distributed in 2010				
7	Amounts treated as distributions out of corpus				
	to satisfy requirements imposed by section				
	170(b)(1)(F) or 4942(g)(3) (see page 27 of the instructions)			,	-
8	Excess distributions carryover from 2004 not		<del></del>		
•	applied on line 5 or line 7 (see page 27 of the				
	instructions)	114,668,984			
9	Excess distributions carryover to 2010.				
	Subtract lines 7 and 8 from line 6a	1,199,054,142			
10	Analysis of line 9.				
а	Excess from 2005 217,845,821				ļ
b	Excess from 2006 221,676,217			ļ	ļ
C	Excess from 2007 177,414,396				
d	Excess from 2008 260,740,827				ì
е	Excess from 2009 321,376,881	1			Į.

### None

Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs: 2

Check here ▶ □ If the foundation only makes contributions to preselected charitable organizations and does not accept unsolicited requests for funds. If the foundation makes gifts, grants, etc. (see page 28 of the instructions) to individuals or organizations under other conditions, complete items 2a, b, c, and d.

The name, address, and telephone number of the person to whom applications should be addressed:

Sanofi-Aventis Patient Assistance Foundation, 55 Corporate Drive, Bridgewater, NJ 08807

b The form in which applications should be submitted and information and materials they should include:

c Any submission deadlines:

### **Not Applicable**

Not Applicable

Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

Award prescription drugs to patients with income below the federal poverty level and not receiving any other assistance.

Part XV Supplementary Information (con			· · · · · · · · · · · · · · · · · · ·	
3 Grants and Contributions Paid During	the Year or Approv	ed for Fu	ture Payment	, <del></del>
Recipient	If recipient is an individual, show any relationship to any foundation manager	Foundation status of	Purpose of grant or contribution	Amount
Name and address (home or business)	or substantial contributor	recipient	Contribution	
a Paid during the year				
See the attached list of prescription drugs that were dispensed free of charge under the Foundation's	None		To provide free drugs	321,376,881
patient assistance program. These products are given out to patients through MDs.			To provide free drugs to patients below pover level and are not	#
(The detail of each recipient's name and address is available upon request. It is a report with hundreds			receiving any other	
of pages.)			receiving any other Assistance	
Total	· · · · · · · · ·	<del></del>	<u> ▶ 3a</u>	321,376,881
<b>b</b> Approved for future payment				
Total <u></u>	<u> </u>	· • · ·	<u> ▶ 3b</u>	<u> </u>

Pa	rt X	Analysis of Income-Producing Ac	dvides				
		ess amounts unless otherwise indicated.	(a) Business code	(b) Amount	(c) Exclusion code	on 512, 513, or 514 (d) Amount	Related or exempt function income (See page 28 of
1	Pro	gram service revenue:					the instructions)
	a						
	þ						
	C						
	d		·				
	6						
	f	<u> </u>					
	9	Fees and contracts from government agencies					
2	Me	mbership dues and assessments				· ·	
3	Inte	rest on savings and temporary cash investments					
4	Div	dends and interest from securities					
5	Net	rental income or (loss) from real estate:					
	а	Debt-financed property					
	b	Not debt-financed property					
6	Net	rental income or (loss) from personal property					
7		er investment income					
8	Gai	n or (loss) from sales of assets other than inventory					
		income or (loss) from special events					
		ss profit or (loss) from sales of inventory					
11	Oth	er revenue: a					
	b						
	C						
	d						
	_						
	e						
12	e Sut	ototal. Add columns (b), (d), and (e)		0		0	
13	e Sub Tot	al. Add line 12, columns (b), (d), and (e)					
<b>13</b> See	Sub Tot	al. Add line 12, columns (b), (d), and (e)	calculations.)		· · · · ·		
13 See Pai	e Sub Tot wor	al. Add line 12, columns (b), (d), and (e) ksheet in line 13 instructions on page 28 to verify /I-B Relationship of Activities to the A	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0
13 See Par Lin	Sub Tot Wor t X	al. Add line 12, columns (b), (d), and (e)	calculations.)	ent of Exemp	t Purposes	13 _ ·	0

								90 .0			
Par	XVII		n Regarding Tra ganizations	nsfers To and Tran	saction	is and	Relationships Wi	th Noncha	ritabi	le	
1	Did t		<del></del>	engage in any of the	following	with ar	v other organization	described	I -	Yes	No
•	ın se			section 501(c)(3) orga						100	
а	-		norting foundation t	to a noncharitable exe	mpt oras	nizatio	n of:		ĺ		
_									1a(1)		1
		ther assets .							1a(2)		1
ь		r transactions:			• •				1 - 1 - 1		
			a noncharitable ex	empt organization .					1b(1)		1
				table exempt organiza					1b(2)		1
				er assets					1b(3)		1
			•						1b(4)		1
			-						1b(5)		1
	(6) P	erformance of se	ervices or members	hip or fundraising soli	citations				1b(6)		1
С	Shari	ng of facilities, e	quipment, mailing l	ists, other assets, or p	aid emp	loyees			1c		✓
d				es," complete the follo							
	value	of the goods, o	ther assets, or serv	ices given by the repo	orting for	undation	n. If the foundation r	eceived less	than	faır m	arket
	value	in any transaction	on or sharing arrang	gement, show in colum	nn (d) the						
(a) Lir	e no. (	(b) Amount involved	(c) Name of nonc	charitable exempt organization	on	(d) Desc	ription of transfers, transf	ctions, and sha	ring arr	angeme	ents
											_
			·								
							·				
		<del></del>									_
	-+			<del></del>				<del>-</del>			
		· <del>-</del>									
				<del></del>			<del></del>	<del></del>			
-											
	-+					· -					
				· ·	-						
		formulation of		ffilina and south and an and a to						-	
za				ffiliated with, or relate other than section 50					1 ./		<b>.</b>
h			e following schedule		1(0)(0)) 01	111 3000	011 027 1		) Yes		NO
	II TE		<del></del>	T			(a) Dose	ription of relation	chio		
		(a) Name of organ	ization	(b) Type of org	anization		(c) Desc	iption of relation	isriip		
			<del></del>				· ·	<u>.</u>			
			<del></del>	<del> </del>			<del></del>			_	
				<del> </del>		<del>- ·</del>					
_			·					<del></del>			
	Lindar -	analties of samuel 1	declare that I have aver	mined this return includes	00000000	una saka	dulae and statements as	nd to the best -	f my le		30.00
				mined this return, including preparer (other than taxpay							
	/	Lich OK	1. Chomson		- /	20/0		"4rer	•		
စု	Sign	ature of officer or trus		·	Date	- /-	Title				
Sign Here	, O.g.				Date	<del></del>	, ,,,,,	Droporaria in	00116		
=	(A						Check if	Preparer's id number (see			n
į	تَ وَ لَ	<b>.</b> .					self-employed ▶ □	page 30 of th	_		
v)	Paic par e O	Preparer's signature									-
	Paid Preparer's Use Onfy	Firm's name (or you	urs if	<del></del>			EIN►				
	_	self-employed), add			<del></del>		Phone no.				-
		1 0110 411 0006	7				i i none no.				

### Schedule B (Form 990, 990-EZ,

Or 990-PF)
Department of the Treasury
Internal Revenue Service

## **Schedule of Contributors**

▶ Attach to Form 990, 990-EZ, or 990-PF.

OMB No 1545-0047

2009

ame of the organization					Employer identification number				
Sanofi-Aventis Patient		43	1614543						
Organization type (che	ck one).								
Filers of:	Se	ction:							
Form 990 or 990-EZ		501(c)( ) (enter number) organization							
		4947(a)(1) nonexempt charitable trust not treated as a	ı prıvate fo	undation	า				
		527 political organization							
Form 990-PF	abla	501(c)(3) exempt private foundation							
		4947(a)(1) nonexempt charitable trust treated as a private foundation							
		501(c)(3) taxable private foundation							
_	_	Form 990, 990-EZ, or 990-PF that received, during the ntributor. Complete Parts I and II.	year, \$5,0	00 or m	ore (in money or				
Special Rules									
sections 509(a)(1	) and 17	anization filing Form 990 or 990-EZ that met the 331/3 9 (b)(1)(A)(vi), and received from any one contributor, dure the amount on (i) Form 990, Part VIII, line 1h or (ii) Form	ring the ye	ar, a cor	ntribution of the greater				
the year, aggregation	ate contr	or (10) organization filing Form 990 or 990-EZ that recountions of more than \$1,000 for use exclusively for religible prevention of cruelty to children or animals. Comple	jious, chari	table, so	cientific, literary, or				
the year, contrib aggregate to mo year for an exclu	For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did not aggregate to more than \$1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the <b>General Rule</b> applies to this organization because it received nonexclusively religious, charitable, etc., contributions of \$5,000 or more during the year.								
990-EZ, or 990-PF), but	it must	not covered by the General Rule and/or the Special Ru inswer "No" on Part IV, line 2 of its Form 990, or chect o certify that it does not meet the filing requirements o	k the box o	on line H	I of its Form 990-EZ,				

Schedule B (Form 990, 990-EZ, or 990-PF) (2009) **Employer identification number** Name of organization 1614543 Sanofi-Aventis Patient Assistance Foundation 43 Contributors (see instructions) Part I (d) (a) (c) Aggregate contributions Type of contribution Name, address, and ZIP + 4 No. 1 Sanofi-Aventis US LLC Person Payroll 55 Corporate Drive 321,376,881 Noncash (Complete Part II if there is Bridgewater, NJ 08807 a noncash contribution) (c) (d) (a) Type of contribution **Aggregate contributions** Name, address, and ZIP + 4 No. Person Payroll Noncash (Complete Part II if there is a noncash contribution) (c) (d) (b) (a) Aggregate contributions Type of contribution No. Name, address, and ZIP + 4 Person Payroll Noncash (Complete Part II if there is a noncash contribution) (d) (b) (c) (a) Type of contribution Name, address, and ZIP + 4 Aggregate contributions No. Person Payroll Noncash (Complete Part II if there is a noncash contribution) (d) (c) (b) (a) Aggregate contributions Type of contribution Name, address, and ZIP + 4 No. Person **Payroll** Noncash (Complete Part II if there is a noncash contribution) (c) (d) (b) (a) Aggregate contributions Type of contribution Name, address, and ZIP + 4 No. Person Payroll Noncash

(Complete Part II if there is a noncash contribution)

Employer identification number

Part II	Noncash Property (see instructions)		
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
.1	Drug_S & Medicines	\$321,376,881	06 <sub>/</sub> 30 <sub>/</sub> 2009
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		\$	<i>I</i>
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		\$	
(a) No. from Part I	(b)  Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		\$	

Sanofi-Aventis Patient A	ssistance Foun	dation		
FEIN: 43-1614543				
12/31/2009				
12/31/2003				
Attachment to Tax Form	990 PE			
Prescription Drug Donat	lion			
Charity Organization	Donated Qty. (units)	Donated Product Name	Unit Selling Price	Total Sale Value
AmeriCares	6,000	Diabeta 2 5mg 100 ct	63 04	378,240 00
AmeriCares	40,930	HCQ 100 ct (malaria)	122 58	5,017,199 40
AmeriCares	1,008	HCQ 500 ct (malaria)	612 86	617,762 88
AmeriCares	503	HCQ 500 ct (malaria)	612 86	308,268 58
AmeriCares	200	Lasix 40 mg 500 ct bottles	238 93	47,786 00
AmeriCares	19,950	Penlac	225 01	4,488,949 50
AmeriCares	10,189	Penlac	225 01	2,292,626 89
AmeriCares*	10,000	Allegra Oral Suspension Samples	7 43	74,300 00
Direct Relief	24,841	Penlac	225 01	5,589,473 41
Direct Relief*	90	Allegra Oral Suspension Samples	7 43	668 70
Direct Relief*	24,000	Allegra Oral Suspension Samples	7 43	178,320 00
Heart to Heart	25,380	Allegra Oral Suspension Samples	7 43	188,573 40
Heart to Heart	5,520	Allegra Oral Suspension Samples	7 43	41,013 60
Heart to Heart	28,936	Allegra Oral Suspension Samples	7 43	214,994 48
Heart to Heart	17,500	Aralan 500 mg	202 49	3,543,575 00
Heart to Heart	5,991	Benzamycın 23 3	46 6	
Heart to Heart	495	Benzamycin 23.3	46 6	
Heart to Heart	4,154	Priftin 150 mg 8 ct blister poucher	28.40	117,973 60
MAP	127	Lovenox 60 mg samples	537 58	68,272 66
MAP	789	Lovenox NovaPlus 120 mg	1,075 50	848,569 50
MAP	2,650	Lovenox NovaPlus 300 mg	268 49	711,498 50
MAP	67	Uroxatral 10 mg 30 ct bottle sample	113 15	7,581 05
MAP	86	Uroxatral 10 mg 7 ct blister sample	26.40	2,270 40
MAP	2,500	Rifadin 150 mg 30 ct	74 31	185,775 00
Sanofi-Aventis Patient Assitance Foundation	992	00160000 DDAVP 1MG TABS 100CT 001600 RX_US	344 54	341,783 68
Sanofi-Aventis Patient		DODGOOD DDAYD COMO TADO OCCOSO DY 110	400.00	4 000 007 04
Assitance Foundation	2,208	00260000 DDAVP 0 2MG TABS 002600 RX_US	496 38	1,096,007 04
Sanofi-Aventis Patient	005	04042500 PENZACUNICEL 25C 040425 DV US	00 47	76,526 55
Assitance Foundation	865	04942500 BENZACLIN GEL 25G 049425 RX_US	88 47	10,520 55
Sanofi-Aventis Patient	60	105104600 RENZAMYCIN GEL 46 6G 051046 PV 119	173 95	11,828 60
Assitance Foundation Sanofi-Aventis Patient	68	05104600 BENZAMYCIN GEL 46 6G 051046 RX_US	1/3 95	11,020 00
Assitance Foundation	34,399	15061600 NASACORT AQ 16 5G 150616 RX_US	93 19	3,205,642 81
Sanofi-Aventis Patient Assitance Foundation	2,141	24500100 DDAVP 01% I-N 2 5ML 245001 RX_US	113 24	242,446 84
Sanofi-Aventis Patient Assitance Foundation	357	24515300 DDAVP INJECTION 1X10ML 245153 RX_US	338 07	120,690 99
Sanofi-Aventis Patient Assitance Foundation	2	50002405 NRPRMN10 100TB BT 000701 RX_US	85 63	171 26
Sanofi-Aventis Patient Assitance Foundation	12	50002419 NRPRMN100 100TB BT 002001 RX_US	323 92	3,887 04
Sanofi-Aventis Patient Assitance Foundation	34	50002422 CANTIL25 100TB BT 003701 RX_US	128 50	4,369 00
Sanofi-Aventis Patient Assitance Foundation	113	50002497 HIPREX 100TB BT 027761 RX_US	179 52	20,285 76
r concerno i ouridation	<u> </u>	1 <u>25 ' 111 11-11 188 18 8 18 18 18 18 18 18 18 18 18 1</u>		

Sanofi-Aventis Patient Ass	istance Foun	dation	1	
FEIN: 43-1614543				
12/31/2009				
1201/2003				
Attachment to Tax Form 99	O DE			
Prescription Drug Donation	<u>n</u>			
Charity Organization	Donated Qty. (units)	Donated Product Name	Unit Selling Price	Total Sale Value
Sanofi-Aventis Patient				
Assitance Foundation	20	50002534 RIFAMT 60HG BT 050960 RX_US	194 02	3,880 40
Sanofi-Aventis Patient				
Assitance Foundation	106	50006101 DIABET2 5 100TB BT 005110 RX_US	54 97	5,826 82
Sanofi-Aventis Patient				
Assitance Foundation	100	50006104 DIABET5 100TB BT 005210 RX_US	100 81	10,081 00
Sanofi-Aventis Patient	76	50006110   ASIVA0 100TB BT 006012 BV US	30.33	2 004 72
Assitance Foundation Sanofi-Aventis Patient	76	50006110 LASIX40 100TB BT 006013 RX_US	38 22	2,904 72
Assitance Foundation	30	50006124 LASIX80 50TB BT 006605 RX_US	30 91	927 30
Sanofi-Aventis Patient	30	00000124	30 91	927 30
Assitance Foundation	1	50006127 LASIX20 100TB BT 006710 RX_US	27 28	27 28
Sanofi-Aventis Patient			2. 20	2, 20
Assitance Foundation	84	50006131 TRENTL400 100FT BT 007810 RX_US	97 78	8,213 52
Sanofi-Aventis Patient				
Assitance Foundation	1,375	50006351 AMARYL1 100TB BT 022110 RX_US	50 24	69,080 00
Sanofi-Aventis Patient				
Assitance Foundation	6,571	50006352 AMARYL2 100TB BT 022210 RX_US	81 43	535,076 53
Sanofi-Aventis Patient				
Assitance Foundation	20,986	50006354 AMARYL4 100TB BT 022310 RX_US	153 57	3,222,820 02
Sanofi-Aventis Patient				
Assitance Foundation	4,069	50011362 ANZEMT20 5IJ VL 120632 RX_US	39 00	158,691 00
Sanofi-Aventis Patient	47.070	50040000 ALLEODDO0400 400TD DT 400047 DV 1104	007.00	0.707.740.40
Assitance Foundation	17,878	50012682 ALLEGRD60/120 100TB BT 109047 RX_US*	207 39	3,707,718 42
Sanofi-Aventis Patient	204	50042447 NI NIDRNIEG 20TR DI 444444 CT DV LIC	400 44	400 007 46
Assitance Foundation Sanofi-Aventis Patient	294	50013147 NLNDRN150 30TB BL 111114 CT RX_US	409 14	120,287 16
Assitance Foundation	2,185	50015382 ANZEMT100 5FT BT 120305 RX_US	317 67	694,108 95
Sanofi-Aventis Patient	2,103		317 07	094,100 95
Assitance Foundation	969	50016101 ARAVA 10MG 30TB BT 216030 RX_US	561 99	544,568 31
Sanofi-Aventis Patient		00010101 744477 10440 0012 27 27 0000 744_00	33,33	311,000 07
Assitance Foundation	6,480	50016104 ARAVA 20MG 30TB BT 216130 RX_US	561 99	3,641,695 20
Sanofi-Aventis Patient	·			
Assitance Foundation	9,130	50017957 ALLEGR60 100FT BT 110747 RX_US*	136 14	1,242,958 20
Sanofi-Aventis Patient				
Assitance Foundation	36,155	50017968 ALLEGR180 100FT BT 110947 RX_US	236 16	8,538,364 80
Sanofi-Aventis Patient				
Assitance Foundation	947,196	50018444 LANTUSIJ 10IJ VL 222033 RX_US	85 97	81,430,440 12
Sanofi-Aventis Patient	0.40	50056543 PENLAC NAIL LCQR 6 6ML BT 800802	400.00	
Assitance Foundation	642	RX_US	180 01	115,566 42
Sanofi-Aventis Patient	20.242	50066572 LOVENOX PREVENTIS 60MG GRAD	400.07	0 700 057 00
Assitance Foundation	20,248	SYR10 50066573 LOVENOX PREVENTIS 80MG GRAD	430 07	8,708,057 36
Sanofi-Aventis Patient	37,877	SYR10	572 42	21 710 909 11
Assitance Foundation Sanofi-Aventis Patient	37,077	50066574 LOVENOX PREVENTIS 100MG GRAD	573 43	21,719,808 11
Assitance Foundation	37,694	SYR10	716 77	27,017,928 38
rissitation i Suridation	01,007	TO THE TOTAL PARTY OF THE TOTAL	1 1011	21,011,320 30

Sanofi-Aventis Patient Ass	istance Foun	dation		
FEIN: 43-1614543				
12/31/2009				
1201/2000				
Attachment to Tax Form 99	10-PF		<u> </u>	
Prescription Drug Donatio				
rescription Drug Donatio	[		<del> </del>	
Charity Organization	Donated Qty. (units)	Donated Product Name	Unit Selling Price	Total Sale Value
Sanofi-Aventis Patient		50066575 LOVENOX PREVENTIS 120MG GRAD		
Assitance Foundation	16,679	SYR10	860 41	14,350,778 39
Sanofi-Aventis Patient		50066576 LOVENOX PREVENTIS 150MG GRAD		
Assitance Foundation	10,960	SYR10	1,075 52	11,787,699 20
Sanofi-Aventis Patient				
Assitance Foundation	139	50067120 KLARON LTN 40Z 750004 RX_US	116 80	16,235 20
Sanofi-Aventis Patient	l			450,000,00
Assitance Foundation	384	50069735 ALLEGRA-D QD 180/240 MG TABS 100 CT	414 80	159,283 20
Sanofi-Aventis Patient	40.050	50000004 ADIDDA 114V40MI VI 250032 DV 110	90.00	2 445 750 50
Assitance Foundation	40,053	50069884 APIDRA IJ 1X10ML VL 250033 RX_US	86 03	3,445,759 59
Sanofi-Aventis Patient Assitance Foundation	180	50070395 NORITATE 60G 985060 RX_US	115 00	20,700 00
Sanofi-Aventis Patient	180		113.00	20,700 00
Assitance Foundation	100,976	50072244 LANTUS SOLOSTAR DISP PEN 5X3ML	166.05	16,767,064 80
Sanofi-Aventis Patient	100,370	Buttoo occount biol 1 cit oxome	100.00	10,707,004 00
Assitance Foundation	2,573	50072246 APIDRA ALPHA DISP PEN 5X3ML	166 20	427,632 60
Sanofi-Aventis Patient		50075771 LOVENOX 30MG W/AUTO SD		
Assitance Foundation	16,826	10SYRG/PKG	214 79	3,614,056 54
Sanofi-Aventis Patient		50075772 LOVENOX 40MG W/AUTO SD		
Assitance Foundation	28,435	10SYRG/PKG	286 37	8,142,930 95
Sanofi-Aventis Patient				
Assitance Foundation	3,565	50085952 XYZAL 5MG TB 90CT BT RX_US	233 29	831,678 85
Sanofi-Aventis Patient				
Assitance Foundation	2,490	50089403 MULTAQ 400MG TB 60CT BT	216 00	537,840.00
Sanofi-Aventis Patient				
Assitance Foundation	609	50090129 APLENZIN 348MG TB 30CT BT RX_US	183 90	111,995 10
Sanofi-Aventis Patient	400	FOODOACO ARI FAIZINI FOOMO TRI COCT RT RV 110	440.50	470 740 00
Assitance Foundation	408	50090130 APLENZIN 522MG TB 30CT BT RX_US	418 50	170,748 00
Sanofi-Aventis Patient Assitance Foundation	199	71503000 CARAC CREAM 0 5% 30GM RX_US	147 54	29,360 46
Sanofi-Aventis Patient	199	71303000 CARAC CREANI 0 376 300N RX_03	147 34	29,300 40
Assitance Foundation	4,281	77006000 RILUTEK 50MG 770060 RX US	884 73	3,787,529 13
Sanofi-Aventis Patient	7,201	77000000 TREGTER COMING 770000 TEX_00	1 004 70	0,707,020 10
Assitance Foundation	13,179	80012000 TAXOTERE 20MG VIAL 800120 RX US	387.10	5,101,590 90
Sanofi-Aventis Patient	10,,			
Assitance Foundation	8,027	80018000 TAXOTERE 80MG VIAL 800180 RX_US	1,548 38	12,428,846 26
Sanofi-Aventis Patient		0000A648 ARALEN PHOSPHATE 500MG TB BTX100		
Assitance Foundation	46	RX_US	161 99	7,451 54
Sanofi-Aventis Patient		0000D523 DRISDOL ERGOCALCIFEROL ORAL		
Assitance Foundation	6	039102 RX_US	119.30	715 80
Sanofi-Aventis Patient		0000D530 DRISDOL ERGOCALCIFEROL CP 039202		
Assitance Foundation	1,942	RX_US	88 62	172,100 04
Sanofi-Aventis Patient				
Assitance Foundation	90	0000E045 ELIGARD 180 DAY 45MG 060545 RX_US	2,466 00	221,940 00
Sanofi-Aventis Patient	==	0005400 5110455 0040 (4440471 5005)	101100	00 000 00
Assitance Foundation	37	000E130 ELIGARD 30MG (4 MONTH DOSE)	1,644 00	60,828 00

Sanofi-Aventis Patient Ass	istance Foun	dation	1	
FEIN: 43-1614543	Ţ			
12/31/2009	-			
12/3 1/2003			<del> </del>	
Attachment to Tax Form 99	On DE			
Prescription Drug Donatio	[]			
			ļ	
			Unit	
	Donated		Selling	Total Sale
Charity Organization	Qty. (units)	Donated Product Name	Price	Value
Sanofi-Aventis Patient				
Assitance Foundation	22	000E501 ELITEK (RASBURICASE)1 5MG VIAL	1,507 18	33,157 96
Sanofi-Aventis Patient	İ	0000E907 ELIGARD 7 5MG LEUPROLIDE 079375		
Assitance Foundation	37	RX_US	411 00	15,207 00
Sanofi-Aventis Patient		0000E910 ELOXATIN AQ SL 50MG/10ML VL 059010		5 405 55 4 55
Assitance Foundation	5,534	RX_US	981 00	5,428,854 00
Sanofi-Aventis Patient		0000E920 ELOXATIN AQ SL 100MG/20ML VL		00 440 050 05
Assitance Foundation	18,578	059120RX_US	1,961 99	36,449,850 22
Sanofi-Aventis Patient		0000E922 ELIGARD 22 5MG LEUPROLIDE 022205	4 000 00	00 000 00
Assitance Foundation	73	RX_US	1,233 00	90,009 00
Sanofi-Aventis Patient	04	10000U042 UVALCAN 40MC/ML 2ML VILBY 40 BY US	104 40	11.054.60
Assitance Foundation	91	0000H212 HYALGAN 10MG/ML 2ML VL BX 10 RX_US 0000H220 HYALGAN 10MG/ML 2ML LUERLOCK SY	121 48	11,054 68
Sanofi-Aventis Patient Assitance Foundation	926	RX_US	121 48	112,490 48
Sanofi-Aventis Patient	920	rx_05	12146	112,430 40
Assitance Foundation	189	0000K450 KAYEXALATE PD 1LB JR	302 06	57,089 34
Sanofi-Aventis Patient	103	10000K430 TATEMENTET B TEB UK	302 00	07,000 04
Assitance Foundation	4	0000M870 MYTELASE 10MG CLT BTX100 RX_US	143 56	574 24
Sanofi-Aventis Patient	<del></del>	OCCUMENT WITH LEGISLE TOWN OF THE TOWN	1.000	0.,2.
Assitance Foundation	17	0000P314 PHISOHEX 50Z 3% BT RX_US	22 27	378 59
Sanofi-Aventis Patient	· · · · · · · · · · · · · · · · · · ·			
Assitance Foundation	11,820	0000P647 PLAQUENIL 200MG TB BTX100 RX_US	221 17	2,614,229 40
Sanofi-Aventis Patient	† <u>'</u>			
Assitance Foundation	2,402	0000X010 UROXATRAL 10MG TB BTX100 RX_US	328 87	789,945 74
National Institute of Health	150	LOVENOX 100MG W/AUTO SD GRAD 062300RX_US	716 77	107,515 50
National Institute of Health	60	LOVENOX 120MG W/AUTO SD GRAD SYR10	860 41	51,624.60
National Institute of Health	30	LOVENOX 150MG W/AUTO SD GRAD SYR10	1,075 52	32,265 60
National Institute of Health	25	LOVENOX 30MG W/AUTO SD 10SYRG/PKG	214 79	5,369 75
National Institute of Health	65	LOVENOX 40MG W/AUTO SD 10SYRG/PKG	286 37	18,614 05
National Institute of Health	169	LOVENOX 60MG W/AUTO SD GRAD SYR10	430 07	72,681 83
National Institute of Health	270	LOVENOX 80MG W/AUTO SD GRAD SYR10	573 43	154,826 10
National Institute of Health	35	TAXOTERE 20MG VIAL 800120 RX_US	373 90	13,086 50
National Institute of Health	275	TAXOTERE 80MG VIAL 800180 RX_US	1,495 58	411,284 50
National Institute of Health	29	Eloxatın AQU 50mg vial	ļ_,_,	
National Institute of Health	150	LOVENOX 100MG W/AUTO SD GRAD 062300RX_US	716 77	107,515 50
National Institute of Health	60	LOVENOX 120MG W/AUTO SD GRAD SYR10	860.41	51,624 60
National Institute of Health	30	LOVENOX 150MG W/AUTO SD GRAD SYR10	1,075 52	32,265 60
National Institute of Health	25	LOVENOX 30MG W/AUTO SD 10SYRG/PKG	214 79	5,369 75
National Institute of Health	65	LOVENOX 40MG W/AUTO SD 10SYRG/PKG	286 37	18,614.05
National Institute of Health	160	LOVENOX 60MG W/AUTO SD GRAD SYR10	430 07	68,811 20
National Institute of Health	270	LOVENOX 80MG W/AUTO SD GRAD SYR10	573 43	154,826 10
National Institute of Health	35	TAXOTERE 20MG VIAL 800120 RX_US	373 90	13,086 50
National Institute of Health	275	TAXOTERE 80MG VIAL 800180 RX_US	1,495 58	411,284 50
Total Donation	1 717 040		<del></del>	221 276 004
Total Donation	1,717,218		<u> </u>	321,376,881